2 citations
,
January 2023 in “Dermatology Practical & Conceptual” AB+ blood group is more common in alopecia areata patients.
2 citations
,
February 2009 in “Journal of Evidence-Based Medicine” No treatment showed significant long-term hair growth benefits for alopecia areata.
1 citations
,
November 2025 in “Clinical Cosmetic and Investigational Dermatology” Sleep patterns might be linked to hair loss, but more research is needed.
1 citations
,
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
1 citations
,
January 2025 in “Frontiers in Immunology” Genetically at-risk healthy people show similar immune issues as those with Pemphigus vulgaris or Alopecia areata.
1 citations
,
December 2024 in “Dermatology and Therapy” The STRIAA tool helps doctors quickly and effectively assess the severity of Alopecia Areata.
1 citations
,
July 2024 in “PharmacoEconomics - Open” The EQ-5D-5L tool may not accurately measure the impact of alopecia areata on patients' lives.
1 citations
,
May 2024 in “AYUSHDHARA” Wet cupping and Rasayana Chikitsa may help regrow hair in alopecia areata.
1 citations
,
January 2024 in “Annals of Dermatology” COVID-19 may trigger alopecia areata, but more research is needed.
1 citations
,
January 2024 in “Annals of Dermatology” Examining hair shape can help predict Alopecia Areata's progression.
1 citations
,
September 2023 in “Clinical, cosmetic and investigational dermatology” Certain genetic variants linked to immune response increase the risk of alopecia areata in Taiwanese people.
1 citations
,
August 2023 in “Acta dermato-venereologica” Corticosteroids are the most common treatment for alopecia areata, but many patients need better options.
1 citations
,
February 2023 in “International Journal of Research in Ayurveda and Pharmacy” Ayurvedic treatment helped a 12-year-old boy regrow hair safely.
1 citations
,
January 2023 in “Przegląd Dermatologiczny” The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.
1 citations
,
September 2022 in “JMIR dermatology” Alopecia Areata greatly affects the quality of life and mental health of Canadian patients and their caregivers.
1 citations
,
December 2020 in “Dermatology Archives” Systemic steroids temporarily improve severe alopecia areata in children but often lead to relapse.
June 2026 in “Frontiers in Immunology” Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.
June 2026 in “Dermatology and Therapy” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
May 2026 in “Research Square” Children with alopecia areata often face more stress and depression, especially related to separation, which can affect their condition.
April 2026 in “Dermatology and Therapy” Baricitinib 4 mg should be used for at least 1 year to see significant hair regrowth in severe alopecia areata.
March 2026 in “American Journal of Clinical Dermatology” Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
March 2026 in “Dermatology and Therapy” Distinct miRNA signatures could help diagnose and treat severe Alopecia Areata.
March 2026 in “Dermatology and Therapy” More severe alopecia areata can lower quality of life.
January 2026 in “AYUSHDHARA” Prachanna followed by Chirabilwa lepa is more effective for alopecia areata than Prachanna followed by Gunja lepa.
January 2026 in “BULLETIN OF STOMATOLOGY AND MAXILLOFACIAL SURGERY” Both treatments help hair regrowth, but Botulinum Toxin-A has fewer side effects.
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.
December 2025 in “International Journal of Research in Ayurveda and Pharmacy” Ayurvedic treatment successfully regrew hair in a 19-year-old with alopecia areata in 2 months.
December 2025 in “Cureus” Higher IL-17A and IL-23 levels are linked to alopecia areata severity and could help in tracking and treating the disease.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in teens with severe alopecia areata.